Physician profile
Tracy L Coe
NPI 1225045529
$11,853.88
in general payments reported to CMS, 2019-2025
33 companies · $504 in 2025
The $504 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $991 · 2021: $2,451 · 2022: $2,566 · 2023: $2,143 · 2024: $1,937 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589 · Long Term Medical Supply Or Device Loan: $750 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,589.46 |
| Long Term Medical Supply Or Device Loan | $749.97 |
| Education | $244.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,664.42 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Incyte Corporation | $1,484.87 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $1,244.76 | 2021-2025 | |
| Janssen Biotech, INC. | $706.81 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $603.74 | 2021-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $499.92 | 2021-2024 | Libtayo |
| Lilly USA, LLC | $493.44 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $440.15 | 2019-2023 | Keytruda, Lynparza |
| Abbvie INC. | $416.39 | 2019-2024 | Epkinly, Venclexta |
| Gilead Sciences, INC. | $357.76 | 2021-2023 | Trodelvy |
| Celgene Corporation | $330.78 | 2019-2021 | |
| Pfizer INC. | $254.76 | 2019-2025 | |
| Seagen INC. | $186.86 | 2021-2023 | Tukysa |
| Genzyme Corporation | $177.47 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $148.90 | 2023 | Xpovio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $142.72 | 2024-2025 | Fruzaqla, Advate |
| Genentech USA, INC. | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2019 | |
| Verastem, INC. | $124.28 | 2020 | |
| Jazz Pharmaceuticals INC. | $123.55 | 2021 | |
| Puma Biotechnology, INC. | $121.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.35 | 2019 | |
| Emd Serono, INC. | $119.03 | 2021 | |
| Stemline Therapeutics INC. | $110.82 | 2023 | Orserdu |
| Eisai INC. | $106.19 | 2019 | |
| Organogenesis INC. | $100.97 | 2020 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Intuitive Surgical, INC. | $99.66 | 2022 | |
| Amgen INC. | $95.63 | 2022 | |
| Kite Pharma, INC. | $94.78 | 2021 | |
| Sanofi-Aventis U.S. LLC | $66.99 | 2022 | |
| Glaxosmithkline, LLC. | $50.46 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Adaptive Biotechnologies Corporation | $14.63 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.